Quote | Aclarion Inc. Warrant (NASDAQ:ACONW)
Last: | $0.0583 |
---|---|
Change Percent: | -24.08% |
Open: | $0.0644 |
Close: | $0.0583 |
High: | $0.0644 |
Low: | $0.03 |
Volume: | 52,991 |
Last Trade Date Time: | 05/02/2024 03:00:00 am |
News | Aclarion Inc. Warrant (NASDAQ:ACONW)
LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a single-payer national health insurance system LIFEHAB is targeting enrollment to begin in the second quarter of 2024 BROOMFIELD, CO,...
Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons. BROOMFIELD, CO, March 04, 2024 (GLOBE NEWS...
Message Board Posts | Aclarion Inc. Warrant (NASDAQ:ACONW)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Aclarion Inc. Warrant Company Name:
ACONW Stock Symbol:
NASDAQ Market:
LIFEHAB is a randomized controlled trial in Norway comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation Norway is a single-payer national health insurance system LIFEHAB is targeting enrollment to begin in the second quarter of 2024 BROOMFIELD, CO,...
Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons. BROOMFIELD, CO, March 04, 2024 (GLOBE NEWS...
BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help...